BUZZ-Amylyx rises after promising early-stage trial for ALS drug
I'm PortAI, I can summarize articles.
Amylyx Pharmaceuticals' shares rose 1.8% to $14.75 premarket after reporting that its experimental ALS drug, AMX0114, was well-tolerated in an early-stage trial with 12 patients. The drug, injected into spinal fluid, aims to protect nerve cells. No serious side effects were reported. The company plans to start enrolling a second group of patients in Canada this month and in the U.S. in January. The stock has increased approximately 283% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments